|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.4200 - 1.6300|
|52 Week Range||0.3400 - 3.7500|
|Beta (5Y Monthly)||3.78|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.75|
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the first patient has been dosed in a commercial setting with its U.S. FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP) for patients with pain from metastatic bone cancer.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP), which has been shown in clinical studies to help relieve persistent pain associated with cancer that has metastasized to bone. In several multicenter, placebo-controlled trials in cancer patients with persistent pain after external beam radiation therapy for bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo*, with a greater percentage of patients experiencing pain scores of zero without any need for opioid or non-opioid rescue analgesics.[2†] Duration of pain palliation has been shown to range from 2 to 5 months in most patients.[1,2] Strontium89 can be redosed every 90 days.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its research partner Mannin Research Inc. (Mannin) is developing new therapeutics to treat a variety of vascular diseases, including the new coronavirus which originated in Wuhan, China, with a rapidly rising number of deaths and confirmed cases. Coronavirus has been declared a Global Health Emergency by the World Health Organization (WHO).
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is pleased to provide the following shareholder letter.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is announcing today that its technology research partner Mannin Research Inc. (Mannin) presented positive data on a potential new treatment for acute kidney injury (AKI). The data was presented at the American Society for Nephrology 2019 Annual Meeting held in Washington DC.
NEW YORK, Nov. 20, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), announces FDA approval of its contract manufacturer IsoTherapeutics Group LLC (ITG). ITG is now cleared to manufacture the Company's FDA approved non-opioid cancer bone pain drug Strontium-89 Chloride USP. The long-awaited approval of the facility means that this important oncologic pain drug will soon be available to patients in the US and the rest of the world.
NEW YORK, Nov. 5, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that its technology partner, Mannin, has received a $7.5M grant from the German state of Saxony. Mannin is a research-stage biotechnology company focused on the discovery, development, and commercialization of therapeutics for vascular diseases.
Jubilant Radiopharma to Distribute Strontium-89 Chloride Injection USP Throughout the United States NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, ...
NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89 Chloride USP. Q BioMed will assume immediate ownership of the drug, including the aNDA (abbreviated new drug application), under a mutually favorable global royalty agreement. Strontium-89 is an important therapeutic option for the treatment of metastatic bone cancer pain.
NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Q BioMed, Inc. (QBIO) and Chemveda Life Sciences are very pleased to announce that after the recent successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the treatment of liver cancer, the two companies have formalized a collaboration to continue the work and to scale-up manufacturing of cGMP product for planned pre-clinical testing and clinical trials. Since February 2017, Q BioMed and Chemveda have been engaged in a joint research program to synthesize uttroside B and several other derivatives. The goal of the program is to study their potential use in clinical trials for the treatment of hepatocellular carcinoma (liver cancer) as well as other cancers.
NEW YORK, Aug. 20, 2019 /PRNewswire/ -- Q BioMed, Inc. (QBIO) and Chemveda Life Sciences are very pleased to announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the treatment of liver cancer. Additional confirmatory cell line efficacy data from current testing is expected to be completed in the next few weeks.
Company provides insights on commercial activities in anticipation of Metastron(TM)/Strontium-89 launch expected later this year New York, New York--(Newsfile Corp. - July 11, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is pleased to announce the latest updates on its non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer.We have been working hard to commercialize both our Strontium-89 products. In addition to the global exclusive license to generic Strontium-89 ...
Currently no effective treatment exists for the 20,000 children in the U.S. and 250,000 born worldwide each year with pediatric minimally verbal autism (PMVA)New York, New York--(Newsfile Corp. - July 2, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has filed an application for Orphan Drug designation with the U.S. FDA's Office of Orphan Product Development for QBM-001, which is designed to treat pediatric minimally verbal autism ...
New York, New York--(Newsfile Corp. - June 24, 2019) - Q BioMed Inc. (OTCQB: QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. As part of the company's effort to bring awareness to our development of several drug candidates to treat a variety of diseases and to highlight the assets in its drug portfolio, the Company's investor relations firm, Cayvan ...
No effective treatment exists for the estimated 250,000 children born worldwide each year with pediatric minimally verbal autism (PMVA), of those approximately 20,000 are born in the U.S. “Children affected by pediatric minimally verbal autism are in dire need of an effective treatment,” stated Q BioMed CEO Denis Corin.
NEW YORK , May 30, 2019 /PRNewswire/ -- 5W Public Relations , one of the 15 largest independently-owned PR firms in the U.S., is pleased to announce it has been named PR Agency of Record for Q BioMed ...
ARVO is the largest and most respected eye and vision research organization in the world. Mannin delegates will be meeting with key partners, researchers, and vendors to further its business development and R&D goals as it relates to progressing the MAN-01 program for treatment of glaucoma into the clinic for its Phase I trial. QBioMed has the global rights to all Mannin Tie2 assets and is working with Mannin Research to accelerate the development and commercialization of MAN-01 and other portfolio assets.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the discovery of two novel biomarkers for pediatric nonverbal autism, identified in a subset of children with Autism Spectrum Disorder (ASD). This marks the first time a company has been able to identify biomarkers that hold the potential to stratify this subset of children.
New York, New York--(Newsfile Corp. - March 27, 2019) - "In the near-term, Q BioMed Inc. (OTCQB: QBIO) has multiple shots on goal with respect to market share, revenue and profit in the multi-billion dollar glaucoma market," says former Piper Jaffray analyst and mutual fund manager Rob Goldman, who now heads up Goldman Small Cap Research.Just weeks after the company announced that it had exercised its option to exclusively license GDF15, a diagnostic marker ...
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Q BioMed (QBIO) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. Based on the novel GDF15 biomarker, this kit's core, platform technology enables more effective measurement and management of glaucoma progression and patient treatment than any current monitoring or therapeutic approaches---a tremendous advantage.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, announced today that its technology partner Mannin Research Inc. has entered into a research collaboration with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression. This enabling technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic with a novel mechanism of action for the treatment of Primary Open-Angle Glaucoma.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Currently, no single examination or diagnostic test is able to accurately predict disease progression.
NEW YORK, NY / ACCESSWIRE / March 7, 2019 / Q BioMed (QBIO), has been getting attention from biotech investors and pharma industry publications for its "upside down" biotech business model. Q BioMed's CEO, Denis Corin, has toldthe investment community that he had no interest in building his firm the same way that had caused so many biotechs to fail. "After my years of experience watching biotech firms collapse under their own weight of debt and financing structures, we set out to put together a biotechnology firm that is very specifically focused on the capital structure of the company, the business operations, being well funded and filled with innovative technologies that we think are under-serviced and under-valued.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. DDNews is a respected monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries.
NEW YORK, Feb. 22, 2019 -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announces multiple interviews with the company’s CEO, Denis Corin, and the Q.